Leading the Way in Life Science Technologies

GEN Exclusives

More »

Market and Technology Analysis

More »
Feb 14, 2014

Next-Gen Sequencing Update

NGS is making waves as it translates from research to the clinic.

Next-Gen Sequencing Update

The approval by the FDA of Illumina’s MiSeqDx platform is a key driver of the translation of NGS toward the clinic. [© taraki - Fotolia.com]

  • We provide an update of the trajectory of the migration of next-generation sequencing (NGS) from the research space toward clinical application and clinical impact in this GEN report as part of our continuing coverage of the evolution of the NGS industry landscape.

    Highlights of this report:

    • There are defined research offerings from several vendors for NGS front-end sample processing and preparation.
    • Many of these kit-formatted products are available and are designed for research use (RUO).
    • There is a defined clinical translation of NGS that is taking place, and one of the key drivers of this translation toward the clinic is the approval of the Illumina MiSeqDx platform by the FDA.
    • Indeed today there are a number of LDTs deploying NGS with specific gene panels—primarily focusing on oncology—but expanding out into other disease classes also.
    • The development of ecosystems of researchers developing NGS-based applications will propel this translation of NGS from research to clinic.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »